Pharmoptima
PharmOptima, a member of Genesis Drug Discovery & Development (GD3), is a contract research organization (CRO) specializing in drug discovery and development services. Since 2003, it has been providing in vitro and in vivo research services, including bioanalytical, biochemistry, and ocular tissue collection, supporting early-stage clinical programs and preclinical research. The company offers customized solutions in various therapeutic areas, with a focus on advancing drug candidates through rigorous testing and analysis. PharmOptima is committed to high-quality data generation, rapid turnaround, and supporting clients from target discovery to IND filing and clinical trial management.
Industries
Nr. of Employees
small (1-50)
Pharmoptima
Portage, Michigan, United States, North America
Services
In vitro ADME assays and in vivo pharmacokinetic studies to assess absorption, distribution, metabolism and excretion.
Ocular efficacy modeling including optic nerve crush and other ophthalmic models with specialized ocular dosing, in-life functional assessments and terminal tissue analyses.
LC-MS/MS method development, validation and sample analysis for small molecules, peptides and large molecules with GLP-capable workflows.
Custom assay development including ELISA and electrochemiluminescence formats, ligand-binding assays, protein expression and purification, antibody labeling and stable cell line generation.
Execution of in vivo pharmacology, efficacy, PK/ADME and tolerance studies with full necropsy, tissue microdissection and sample processing workflows.
Assay development and validation for quantifying SMN protein in small-volume whole-blood samples to support baseline and drug-response biomarker programs.
In vitro ADME assays and in vivo pharmacokinetic studies to assess absorption, distribution, metabolism and excretion.
Ocular efficacy modeling including optic nerve crush and other ophthalmic models with specialized ocular dosing, in-life functional assessments and terminal tissue analyses.
LC-MS/MS method development, validation and sample analysis for small molecules, peptides and large molecules with GLP-capable workflows.
Custom assay development including ELISA and electrochemiluminescence formats, ligand-binding assays, protein expression and purification, antibody labeling and stable cell line generation.
Execution of in vivo pharmacology, efficacy, PK/ADME and tolerance studies with full necropsy, tissue microdissection and sample processing workflows.
Assay development and validation for quantifying SMN protein in small-volume whole-blood samples to support baseline and drug-response biomarker programs.
Expertise Areas
- DMPK/ADME and preclinical pharmacokinetics
- Bioanalytical method development and GLP validation
- Biomarker assay development for proteins and oligonucleotides
- Ocular pharmacology and ocular tissue processing
Key Technologies
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
- Electrochemiluminescence immunoassays
- Enzyme-linked immunosorbent assays (ELISA)
- Nuclease protection assays for oligonucleotides
News & Updates
May 4 - 8, Salt Lake City, Utah, Booth #: 1322.
April 25-30, Chicago, Illinois, Booth #: 4913.
April 25, 2025, Cambridge, Massachusetts.
March 16-20, 2025, Orlando, Florida, Booth #: 1100.
A 2023 preprint study on optic nerve injury.
May 4 - 8, Salt Lake City, Utah, Booth #: 1322.
April 25-30, Chicago, Illinois, Booth #: 4913.
April 25, 2025, Cambridge, Massachusetts.
March 16-20, 2025, Orlando, Florida, Booth #: 1100.
A 2023 preprint study on optic nerve injury.